BioCryst Pharmaceuticals | BCRX - Selling And Administration Expenses


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals reported $47.87M in Selling and Administration Expenses for its fiscal quarter ending in March of 2023.


Selling And Administration Expenses Change
Alnylam Pharmaceuticals ALNY:US USD 183.66M 26.68M
BioCryst Pharmaceuticals BCRX:US USD 47.87M 2.29M
Chugai Pharma 4519:JP JPY 21.02B 9.86B
Daiichi Sankyo 4568:JP JPY 140.41B 19.45B
Enanta Pharmaceuticals ENTA:US USD 13.78M 1.08M
Gilead Sciences GILD:US USD 1.32B 702M
GlaxoSmithKline GSK:LN GBP 2.06B 370M
Glaxosmithkline GSK:US GBP 2.06B 370M
Incyte Corp INCY:US USD 315.61M 42.79M
Intra Cellular Therapies ITCI:US USD 98.92M 4.29M
Ionis Pharmaceuticals IONS:US USD 45.52M 2.43M
Karyopharm Therapeutics KPTI:US USD 35.91M 1.26M
Mirati Therapeutics MRTX:US USD 73.49M 2.67M
Neurocrine Biosciences NBIX:US USD 242.7M 59.8M
Novavax NVAX:US USD 112.53M 49.13M
PTC Therapeutics PTCT:US USD 86.91M 5.8M
Regeneron Pharmaceuticals REGN:US USD 601.1M 59.4M
Roche Holding ROG:VX CHF 6.48B 834M
Sarepta Therapeutics SRPT:US USD 110.71M 9.76M
Ultragenyx Pharmaceutical RARE:US USD 76.65M 3.8M
Vertex Pharmaceuticals VRTX:US USD 241.1M 26.3M